Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region
4.9.2023 11:00:00 EEST | Business Wire | Press release
Eigenmann & Veronelli S.p.A., a leading distributor in the specialty chemicals and food ingredients industry, today announced that it has acquired 100% of IMEA Technologies FZC, a regional distribution company of specialty chemicals with a focus on the industrial market, based in the United Arab Emirates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904875181/en/
Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region. (Photo: Business Wire)
The acquisition represents an excellent fit with E&V’s existing operations and a strategic commercial expansion in the Middle East and Africa region, in addition to the Far East and Indian markets, reinforcing its international footprint to consolidate its compelling portfolio and execute its growth strategy.
IMEA Technologies was founded in 2011, in Sharjah (U.A.E.), and offers a wide range of products, mainly industrial, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetic & cleaning applications.
Headquartered in Sharjah, with offices & warehouses in U.A.E., the Company ensures the full coverage of the MEA region in addition to the Far East and Indian markets. In 2022, IMEA Technologies generated revenues of approximately AED 68.5M (ca. EUR 17.7 million).
IMEA Technologies, as part of the E&V Group, will be led by its present management line-up and staff retaining its well-established name.
Gabriele Bonomi, Chief Executive Officer of the E&V Group, comments:
“In line with our strategic vision to be an established international solutions provider, we are delighted to welcome IMEA Technologies to the E&V Group. This acquisition strengthens our international footprint and allows us to offer a truly compelling value proposition to both principals and customers.”
Ayoob Chekkintakath, Executive Director of IMEA Technologies, adds:
“Becoming part of E&V, a key international market player, marks a milestone in our company’s evolution. We share a similar vision and culture, and I am confident that IMEA Technologies will continue to thrive as part of the E&V Group, continuing its long-term relationships with key suppliers and customers.”
ABOUT EIGENMANN & VERONELLI S.p.A.
Eigenmann & Veronelli is an international solutions provider in the specialty chemicals and food ingredients industry with a direct presence in 4 countries and a commercial reach in more than 30. Headquartered in Rho, Milan, Italy, E&V is synonymous with effectiveness and efficiency, combining local market knowledge with international chemical innovations. In 2022 the E&V Group generated a consolidated turnover of EUR 417 M with 340 employees.
To find out more about E&V, please visit: www.eigver.com
ABOUT IMEA TECHNOLOGIES FZC
IMEA Technologies is a regional distributor of specialty chemicals, specialized in industrial market, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetics & cleaning applications. Headquartered in Saif Zone, Sharjah (U.A.E.), with offices and warehouses in U.A.E. IMEA Tech. posted a consolidated turnover of EUR 17.7 M in 2022.
To find out more, please visit: www.imeatech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904875181/en/
Contact information
Press Contact
Federica Urso
Group Corporate Communication Manager, E&V S.p.A
mediarelations@eigver.it - +39 338.7295116
Commercial Contact
Ayoob Chekkintakath
Executive Director, IMEA TECHNOLOGIES FZC
info@imeatech.com - +971 6 5574800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 07:00:00 EEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom